BlockBeats News, December 31st, Neo Co-Founder and Core Developer Erik Zhang accused NEO Founder Da Hongfei of failing to fulfill the commitment to financial disclosure. Erik Zhang stated that based on a clear agreement reached in a recent phone call, starting from January 1, 2026, Da Hongfei will focus on the operation and development of NeoX and SpoonOS, no longer involved in any matters related to the Neo mainnet, and called on Da Hongfei to immediately make a complete and verifiable financial report public to the community, including a detailed list of all assets managed by the Neo Foundation (NF) and a breakdown of all expenditures to address the community's long-standing concerns about transparency and governance.
NEO Founder Da Hongfei responded in a post, stating that Erik Zhang controls the vast majority of Neo funds, manipulates consensus node voting, and is willing to hijack agreements at the expense of the community and token holders' interests. He had urged Erik to transfer NEO/GAS tokens from his personal custody to the foundation's multisig address — he still retains the key holder status. However, Erik Zhang always finds excuses to delay this process.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.






Key Takeaways Bybit plans to introduce “MyBank” dollar accounts in partnership with licensed financial institutions, enhancing seamless conversion…









Latest Crypto Market Snapshot as of August 22, 2025 BTC Soars to $115,250.00 ETH Hits $4,450.75 XRP Climbs…

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.














Key Takeaways Bybit plans to introduce “MyBank” dollar accounts in partnership with licensed financial institutions, enhancing seamless conversion…